Key result
Higher endothelin-1 levels were more strongly associated with adverse cardiovascular outcomes in men (HR 2.62) compared to women (HR 1.14) with chronic heart failure.
Why the study?
Studies focusing on sex differences in circulating proteins in patients with HFrEF are scarce, and insight into sex-specific cardiovascular protein profiles and their associations with adverse outcomes was needed.
Cohort (n=382)
Yes
Answers are grounded in this paper and cite their sources.
Baseline cardiovascular protein levels differ significantly between men and women with HFrEF, and the prognostic value of specific proteins like endothelin-1 and somatostatin is modified by sex, suggesting a need for sex-specific risk stratification.
Background Studies focusing on sex differences in circulating proteins in patients with heart failure with reduced ejection fraction (HFrEF) are scarce. Insight into sex-specific cardiovascular protein profiles and their associations with the risk of adverse outcomes may contribute to a better understanding of the pathophysiological processes involved in HFrEF. Moreover, it could provide a basis for the use of circulating protein measurements for prognostication in women and men, wherein the most relevant protein measurements are applied in each of the sexes. Methods In 382 patients with HFrEF, we performed tri-monthly blood sampling (median follow-up: 25 [13–31] months). We selected all baseline samples and two samples closest to the primary endpoint (PEP: composite of cardiovascular death, heart transplantation, left ventricular assist device implantation, and HF hospitalization) or censoring. We then applied an aptamer-based multiplex proteomic assay identifying 1105 proteins previously associated with cardiovascular disease. We used linear regression models and gene-enrichment analysis to study sex-based differences in baseline levels. We used time-dependent Cox models to study differences in the prognostic value of serially measured proteins. All models were adjusted for the MAGGIC HF mortality risk score and p-values for multiple testing. Results In 104 women and 278 men (mean age 62 and 64 years, respectively) cumulative PEP incidence at 30 months was 25% and 35%, respectively. At baseline, 55 (5%) out of the 1105 proteins were significantly different between women and men. The female protein profile was most strongly associated with extracellular matrix organization, while the male profile was dominated by regulation of cell death. The association of endothelin-1 (Pinteraction < 0.001) and somatostatin (Pinteraction = 0.040) with the PEP was modified by sex, independent of clinical characteristics. Endothelin-1 was more strongly associated with the PEP in men (HR 2.62 [95%CI, 1.98, 3.46], p < 0.001) compared to women (1.14 [1.01, 1.29], p = 0.036). Somatostatin was positively associated with the PEP in men (1.23 [1.10, 1.38], p < 0.001), but inversely associated in women (0.33 [0.12, 0.93], p = 0.036). Conclusion Baseline cardiovascular protein levels differ between women and men. However, the predictive value of repeatedly measured circulating proteins does not seem to differ except for endothelin-1 and somatostatin.
No takes yet. Share an insight, caveat, or question.
Bakker et al. (2023) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=382). Endothelin-1 level (in men) vs. Lower endothelin-1 level was evaluated on Composite of cardiovascular death, heart transplantation, left ventricular assist device implantation, and heart failure hospitalization (HR 2.62, 95% CI 1.98-3.46, p=<0.001). Higher endothelin-1 levels were more strongly associated with adverse cardiovascular outcomes in men (HR 2.62) compared to women (HR 1.14) with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: